Department of Psychiatry, School of Medicine, Yasuj University of Medical Sciences, Yasuj, Iran.
Medicinal Plants Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.
BMC Psychiatry. 2024 Jan 12;24(1):44. doi: 10.1186/s12888-023-05429-w.
According to the Institute of Health Metrics and Evaluation's Global Health Data Exchange (2023) it is estimated that 5% of all adults will experience depressive disorder. Amongst the general loss of pleasure and interest in everyday activities that are symptoms of low mood, reduced sexual desire and sexual dysfunction can be particularly overlooked. Human sexuality is complex, but finding solutions based on scientific evidence to limit the symptoms of depressive disorder and the iatrogenic impact of antidepressant treatment to improve this outcome is an important step in promoting psychological health and general wellbeing.
The present study aimed is to provide scientific evidence to assess the effect of oral probiotic on sexual function in women with depressive disorder treated with Selective Serotonin Reuptake Inhibitors (SSRIs) in an Iranian population.
This study was a double-blind randomized clinical trial. Eligible women were assigned to lactofem plus SSRIs (n = 58) or SSRIs alone (n = 54). In group A, SSRI antidepressants were prescribed together with Lactofem, and in group B, SSRI antidepressants were prescribed alone. Lactofem including Lactobacillus acidophilus 2 × 10 cfu/g, Bifidobacterium bifidus 2 × 10 cfu/g, Lactobacillus rutri 2 × 10 cfu/g, Lactobacillus fermentum 2 × 10 cfu/g; capsule weight of 500 mg bio-capsule administered orally and daily. The duration of intervention in two groups was two months. All questionnaires were completed by the patients before and after the intervention. The Female Sexual Function Index (FSFI), Hamilton Depression Rating Scale and Larson's Sexual Satisfaction Questionnaire were used to evaluate sexual function, severity of depressive disorder and sexual satisfaction, respectively.
Based on the results of the present study, there was a statistically significant difference in sexual satisfaction and severity of depressive disorder between the groups before and after the intervention (P < 0.05). Also, our findings showed that after eight weeks, the Lactofem plus SSRIs group showed significant improvement in FSFI domains and total scores compared to SSRIs alone group (P < 0.05).
The results of the present study show that taking probiotics for eight weeks may improve the severity of depressive disorder, sexual function and sexual satisfaction in depressed women treated with SSRIs.
ClinicalTrials.govidentifier: IRCT20160524028038N14 (19/12/2022).
根据健康指标与评估研究所的全球卫生数据交换(2023 年),估计所有成年人中有 5%会经历抑郁障碍。在日常活动中普遍失去乐趣和兴趣的症状中,性欲减退和性功能障碍可能特别容易被忽视。人类的性行为很复杂,但基于科学证据找到解决方案,以限制抑郁障碍的症状和抗抑郁药物治疗的医源性影响,从而改善这一结果,是促进心理健康和整体幸福感的重要一步。
本研究旨在提供科学证据,评估口服益生菌对伊朗人群中接受选择性 5-羟色胺再摄取抑制剂(SSRIs)治疗的抑郁障碍女性性功能的影响。
这是一项双盲随机临床试验。合格的女性被分配到乳杆菌加 SSRIs(n=58)或单独 SSRIs(n=54)组。在 A 组中,同时开 SSRIs 抗抑郁药和乳杆菌,在 B 组中,单独开 SSRIs 抗抑郁药。乳杆菌含有嗜酸乳杆菌 2×10cfu/g、双歧杆菌 2×10cfu/g、罗特乳杆菌 2×10cfu/g、发酵乳杆菌 2×10cfu/g;胶囊重量为 500mg 生物胶囊,口服,每日一次。两组的干预时间均为两个月。所有问卷均由患者在干预前后填写。使用女性性功能指数(FSFI)、汉密尔顿抑郁评定量表和拉森性满意度问卷分别评估性功能、抑郁障碍严重程度和性满意度。
根据本研究的结果,两组患者在干预前后的性满意度和抑郁障碍严重程度均有统计学意义(P<0.05)。此外,我们的研究结果表明,八周后,与单独使用 SSRIs 相比,乳杆菌加 SSRIs 组在 FSFI 各领域和总分方面均有显著改善(P<0.05)。
本研究结果表明,服用益生菌八周可能会改善接受 SSRIs 治疗的抑郁女性的抑郁障碍严重程度、性功能和性满意度。
ClinicalTrials.gov 标识符:IRCT20160524028038N14(2022 年 12 月 19 日)。